INM News and Press, InMed Pharmaceuticals Inc. From 09/29/23

Completed Phase 2 Clinical Trial demonstrating anti-itch activity of INM-755 (CBN) topical cream $4.1M revenues in fiscal year 2023, representing a 280% increase over the previous fiscal year and $2.3M revenues in fiscal Q4 2023, representing 123% increase quarter over quarter ("QoQ") Stren...

Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-06-30 Humanigen Inc. (HGEN) is expected to report for Q2 2023 Ever-Glory International Group Inc. (EVKG) is expected to report for quarter end 2023-06-30 SunCar Technology Group Inc. (SDA) is expected to ...

2023-09-26 05:08:33 ET More on InMed Pharmaceuticals Historical earnings data for InMed Pharmaceuticals Financial information for InMed Pharmaceuticals For further details see: InMed Pharmaceuticals receives Nasdaq notice for non-compliance

Regenicin Inc (RGIN) is expected to report for quarter end 2023-06-30 Grasim Industries Ltd. ADR (GRSXY) is expected to report for quarter end 2023-06-30 Mitsubishi Heavy Industries Ltd. (MHVYF) is expected to report for Q1 2024 Japan Tobacco Inc. ADR (JAPAY) is expected to report $0....

InMed Pharmaceuticals Inc. (INM) is expected to report for Q4 2023

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs, today announced its participation in the H.C. Wainwright Global Investment Conference, which is taking place Sept. 11-13, ...

Vancouver, British Columbia--(Newsfile Corp. - September 7, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs, today announce th...

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a ...

Vancouver, British Columbia--(Newsfile Corp. - July 21, 2023) - InMed Pharmaceuticals Inc. ( NASDAQ: INM ) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce Jerry G...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical ra...